Patents by Inventor Thaddeus Peter Dryja
Thaddeus Peter Dryja has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230323398Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: ApplicationFiled: January 26, 2023Publication date: October 12, 2023Inventors: Chad Eric BIGELOW, Vivian CHOI, Thaddeus Peter DRYJA, Akshata Ninad GUJAR, Shawn Michael HANKS, Terri MCGEE, Seshidhar Reddy POLICE, Joanna VROUVLIANIS
-
Publication number: 20210047656Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: ApplicationFiled: December 23, 2019Publication date: February 18, 2021Inventors: Vivian CHOI, Chad Eric BIGELOW, Thaddeus Peter DRYJA, Seshidhar Reddy POLICE
-
Patent number: 10550404Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: GrantFiled: September 22, 2017Date of Patent: February 4, 2020Assignee: NOVARTIS AGInventors: Vivian Choi, Chad Eric Bigelow, Thaddeus Peter Dryja, Seshidhar Reddy Police
-
Patent number: 10537648Abstract: The invention provides compositions for rendering a vitreous cavity visible during a surgical procedure to alleviate a structural disorder caused by the vitreous in an eye, and methods of using the compositions. The compositions are vitreous delineating agents that comprise a hyaluronan binding peptide linked to an optically detectable moiety. Such compositions can be in a formulation that may be a solution, a suspension, or an emulsion, and would be injected into the vitreous shortly prior to use. The composition may additionally contain a therapeutic agent, a diagnostic agent, or a chemosensing material, in use, the composition marks or delineates the vitreous by binding preferentially to the hyaluronan that permeates the vitreous humor and binding little or not at all to surrounding tissues such as the retina.Type: GrantFiled: June 24, 2015Date of Patent: January 21, 2020Assignee: Novartis AGInventors: Joy Ghosh, Thaddeus Peter Dryja, Michael Roguska, Eric C. Carlson
-
Publication number: 20180080046Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: ApplicationFiled: September 22, 2017Publication date: March 22, 2018Applicant: Novartis AGInventors: Vivian CHOI, Chad Eric BIGELOW, Thaddeus Peter DRYJA, Seshidhar Reddy POLICE
-
Patent number: 9803217Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: GrantFiled: October 13, 2015Date of Patent: October 31, 2017Assignee: NOVARTIS AGInventors: Vivian Choi, Chad Eric Bigelow, Thaddeus Peter Dryja, Seshidhar Reddy Police
-
Publication number: 20170202981Abstract: The invention provides compositions for rendering a vitreous cavity visible during a surgical procedure to alleviate a structural disorder caused by the vitreous in an eye, and methods of using the compositions. The compositions are vitreous delineating agents that comprise a hyaluronan binding peptide linked to an optically detectable moiety. Such compositions can be in a formulation that may be a solution, a suspension, or an emulsion, and would be injected into the vitreous shortly prior to use. The composition may additionally contain a therapeutic agent, a diagnostic agent, or a chemosensing material, in use, the composition marks or delineates the vitreous by binding preferentially to the hyaluronan that permeates the vitreous humor and binding little or not at all to surrounding tissues such as the retina.Type: ApplicationFiled: June 24, 2015Publication date: July 20, 2017Applicant: Novartis AGInventors: Joy GHOSH, Thaddeus Peter DRYJA, Michael ROGUSKA, Eric C. CARLSON
-
Publication number: 20160097061Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: ApplicationFiled: October 13, 2015Publication date: April 7, 2016Applicant: NOVARTIS AGInventors: Vivian CHOI, Chad Eric BIGELOW, Thaddeus Peter DRYJA, Seshidhar Reddy POLICE
-
Patent number: 9163259Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: GrantFiled: April 30, 2013Date of Patent: October 20, 2015Assignee: Novartis AGInventors: Vivian Choi, Chad Eric Bigelow, Thaddeus Peter Dryja, Seshidhar Reddy Police
-
Publication number: 20140017201Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: ApplicationFiled: April 30, 2013Publication date: January 16, 2014Applicant: NOVARTIS AGInventors: Vivian Choi, Chad Eric Bigelow, Thaddeus Peter Dryja, Seshidhar Reddy Police